AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01071356 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Single session MI
Description: Comparator arm that includes 1.5 hours of MI, 8 hours of nutrition classes and outpatient substance abuse treatment
Study NCT01653899 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IDN-6556
Description: 14 day oral treatment of the investigational caspase inhibitor drug IDN-6556 following first islet transplant at 50mg twice daily.
Study NCT04058704 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Icotinib
Description: 125mg Tid/375mg per day
Study NCT04058704 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: SRS/WBRT/HA-WBRT/SMART
Description: >3 with WBRT/HA-WBRT/SMART or 1-3 with SRS
Study NCT01605318 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Labetuzumab Govitecan (LG)
Description: Administered as a slow intravenous (IV) infusion.
Study NCT04183491 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Peginterferon beta-1a
Description: Peginterferon beta-1a 125 µg administered SC
Study NCT04183491 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (administered either IM or SC)
Study NCT04602949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breath Biopsy Analysis
Description: Analysis of a single breath Biopsy
Study NCT02337699 — intervention group
Intervention type: DEVICE
Intervention: Implantation with the commercially available Axium neurostimulator
Study NCT02337699 — intervention group
Intervention type: PROCEDURE
Intervention: QST Testing
Study NCT02018874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2780301
Description: LY2780301 will be given orally Q.D. at different dose levels. Because of a favourable safety profile, the different dose levels will be as follow :~* Dose level -1: 300 mg Q.D.~* Dose level -0.5: 400 mg Q.D.~* Dose level 1: 400 mg Q.D.~* Dose level 1.5: 500 mg Q.D.~* Dose level 2 : 500 mg Q.D.
Study NCT02018874 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: The dose level of Gemcitabine will be fixed (1000 mg/m2). Gemcitabine will be administered over a 30 minutes infusion.
Study NCT03237130 — intervention group
Intervention type: PROCEDURE
Intervention: preoperative enhanced chest CT examination
Description: Each patient will receive preoperative enhanced chest CT examination, and their CT images will be used for analysis
Study NCT03738007 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HA IDF II
Description: Treatment with HA IDF II (YVOIRE volume)
Study NCT03738007 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Perlane
Description: Treatment with Perlane
Study NCT05749653 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bi-annual CDTI
Description: Bi-annual CDTI
Study NCT00837018 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: physical exercise program
Description: 45 min, 3times a week
Study NCT01283490 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: DASD Group
Description: Single application of 20% Benzocaine applied for one minute with the DASD ultrasonic and sonic vibration prior to needle puncture.
Study NCT01283490 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sonic Vibration (SV)
Description: Single application of 20% benzocaine applied with SV for one minute prior to needle puncture.
Study NCT02713516 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: Use of virtual reality to deliver exposure therapy
Study NCT00143533 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Irinotecan, Cefpodoxime
Description: See Detailed description section for treatment details.
Study NCT03927352 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: SCT630
Description: Administered by subcutaneous injection
Study NCT03927352 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered by subcutaneous injection
Study NCT03734068 — intervention group
Intervention type: DEVICE
Intervention: Chemoembolization Using LifePearl
Description: Chemoembolization Using LifePearl
Study NCT03734068 — intervention group
Intervention type: DRUG
Intervention: Doxorubicin
Description: Doxorubicin is loaded to LIfePearl
Study NCT03631212 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Flexiquit
Description: Digital avatar-led Acceptance and Commitment Therapy for smoking cessation
Study NCT03315169 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: External dressing
Description: Application of external dressing whilst perianal abscess cavity heals.
Study NCT03315169 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Packing of perianal abscess cavity
Description: Internal packing of perianal abscess cavity - standard treatment.
Study NCT00955604 — intervention group
Intervention type: DRUG
Intervention: Group R+AD Rasagiline + Antidepressant
Description: Rasagiline and an antidepressant (SRIs, SNRIs, St. John's wort and/or TCAs) at least 14 days
Study NCT00955604 — intervention group
Intervention type: DRUG
Intervention: Group R Rasagiline
Description: At least 2 months of rasagiline
Study NCT00955604 — intervention group
Intervention type: DRUG
Intervention: Group AD Anti-PD + Antidepressant
Description: An approved dopaminergic medication for PD. (2 months of treatment with an antidepressant medication.
Study NCT02437786 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GRAZAX
Description: GRAZAX
Study NCT02534662 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ENDOMINA
Description: Endomina will be introduced into the stomach over guide wires and then fixed to the endoscope. The procedure will include the placement of 4-6 transmural anterior-posterior sutures after argon plasma coagulation of the tissue opposition areas in order to ensure persistence of the pouch reduction. Patient will be kept overnight after the procedure.
Study NCT00737594 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo capsules for oral administration
Study NCT00737594 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cobiprostone
Description: Cobiprostone capsules for oral administration
Study NCT02739321 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sound to Sleep System
Description: Sound to Sleep System is a minimal risk device that is embedded in a mattress boxspring. The device syncs with an audio input and emits tactile vibrations in sync with the audio input.
Study NCT01231815 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: 15O-H2O PET -
Description: Assessment of coronary reserve using PET
Study NCT01231815 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: MRI
Description: Assessment of coronary reserve using MRI
Study NCT03414684 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab works by attaching to and blocking a molecule called PD-1. PD-1 is a different molecule that can turn off the immune system by interacting with PD-L1 on the cancer cells
Study NCT01522612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: 500 mg/m2 on day 1, Every 14 days Intravenously
Study NCT04114799 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hemodynamic management based on invasive fluid responsiveness parameters
Description: In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the SPV value more than 8% will be used as a trigger for the bolus of 2 ml/kg of Plasmalyte (Baxter)
Study NCT04114799 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodynamic management based on noninvasive cardiac output and SVV measurement
Description: In case of hypotension (reduction of MAP for more than 15% of individual blood pressure) the systemic vascular resistance (SVR) value will be used to trigger norepinephrine infusion. In patients with low SVR norepinephrine infusion will be started. In patients with high SVR value either fluid bolus (in patient with SVV value above 8%), or dobutamine infusion (in patients with SVV value below or equal 8%) will be used.
Study NCT02302235 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Ketogenic Diet
Description: Treatment will consist of ketogenic diet. KD will consist of 4:1 \[fat\] : \[protein+carbohydrate\] weight ratio with 1600 kcal restriction.
Study NCT02302235 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standardized Diet
Description: Participants with GBM treated with radiation and temozolomide after surgical debulking treatment. The subjects will be taken standard diet in a 1:1 ratio. Diet will be started at the time of initiation of radiation treatment.
Study NCT04664530 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: esketamine
Description: The in-hospital intervention process is divided into a titration phase and an effect evaluation phase. After admission, all patients received pregabalin 150mg twice for one day and amitriptyline 12.5mg one piece per night. The treatment group was combined with intranasal esketamine three times per day, and individualized concentration titration was performed within 5 days. Set the initial dosage to 10mg for nasal drops. If the score is less than 5 points compared to the basic value, the dose is increased by 5 mg each time. When the dose reaches 25mg, the increment of the dose will be adjusted to 10mg. If the score is reduced by ≥5 points compared to the basic value, the current dose will be maintained and the titration will end. The titration phase will be finished when the titration dose reaches 35mg or untolerable adverse reactions occurs. Finally, a 7 tesla scan was performed on the right-hand patients with herpes on the body to explore the effect of ketamine on the brain network.
Study NCT04664530 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: The titration process in the control group with saline are the same as those in the treatment group with esketamine.
Study NCT01288612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sedated Endoscopy
Description: The sedated esophagogastroduodenoscopy procedures were performed using a conventional high-definition endoscope (GIF-180, Olympus America, Center Valley, Pennsylvania) under conscious sedation with intravenous midazolam and fentanyl.
Study NCT01288612 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transnasal Endoscopy
Description: Unsedated transnasal endoscopy performed using the EndoSheath transnasal esophagoscope (TNL-5000, Vision Sciences). Topical anesthetic aerosol spray was applied to the posterior pharynx and nasal spray mixture was applied to the patients nares 10-15 minutes before the endoscopy procedure.
Study NCT00030771 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemotherapy
Description: Docetaxel (Taxotere®) 85 mg/m2 1 hour iv infusion d1 Cisplatin 100 mg/m2 1 hour iv infusion d1 Schedule: 3 cycles repeated every 21 days
Study NCT00030771 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Radiotherapy
Description: Radiotherapy (3 weeks after last chemotherapy administration) 44 Gy in 22 fractions concomitant boost technique in 3 weeks
Study NCT00030771 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Surgery
Description: 3-4 weeks after termination of radiotherapy
Study NCT03790774 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Participants receive intermittent visual and auditory cues to adjust their attentional engagement with a letter identification task.
Study NCT01357824 — intervention group
Intervention type: PROCEDURE
Intervention: Application of Sellick´s maneuver.
Description: The patient will be intubated with a flexible fiberscope, Olympus model, under the application of Sellick´s maneuver, with the recommended 30 Newtons pressure, and also, as control, be intubated with a sham Sellick´s maneuver, with 0 Newton. The order of the pressures is randomized, and it is blinded to the intubating physician by a cloth which of the maneuvers that is used. The pressure is measured be a pediatric cuff, which is pressed against the throat.
Study NCT02120495 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: condylectomy
Description: The condylectomy via intraoral approach will avoid the risk of facial nerve injury and skin scar compared with the preauricular incision.And it can also greatly reserve the temporomandibular jiont anatomy and function.
Study NCT01371799 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Drug
Description: Placebo
Study NCT01344044 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BCI
Description: 24 half-hour sessions over 8 weeks, i.e. 3 sessions per week, followed by 3 once-monthly boosters.
Study NCT03978429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Community-based Pre-eclampsia/Eclampsia Detection and Management
Description: Three Community Health Workers (CHWs) per health facility (cluster) will be equipped with android smartphones and blood pressure monitors. The CHWs will visit participant's home once per month until 6 weeks post-partum and complete a Case Report Form for signs and symptoms of pre-eclampsia and blood pressure. CHWs, Antenatal Care Nurses (ANC) at the woman's health facility and study coordinator will receive SMS message if the algorithm on our platform (informed by the Tanzanian Standard Treatment Guidelines (TSTG) deems she is at risk for pre-eclampsia. This message will indicate that the woman needs to be referred to her health facility if: participant has high blood pressure, a significant intrapatient rise in blood pressure or a combination of factors according to an algorithm. Woman's condition will be assessed and ANC will decide on the management, including rest at home with CHW monitoring. Women found to be at risk for pre-eclampsia will be visited twice monthly.
Study NCT01522612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil
Description: Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
Study NCT01522612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: Every 2 weeks, 400 mg/m2 on day 1; 2400 mg/m2 from day 1 to day 3, intravenously
Study NCT01522612 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: leucovorin
Description: Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
Study NCT01522612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin
Description: Every 2 weeks, Racemic leucovorin 200 mg/m2 or l-leucovorin 100 mg/m2 on day 1, intravenously
Study NCT04602949 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Breath Biopsy Analysis
Description: Analysis of a single breath Biopsy
Study NCT01034488 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Suine
Description: 5000UI /mL
Study NCT03978429 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Strengthened Referral Network from Community to Referral hospital levels
Description: ANC nurses and CHWs will play complementary roles in performing activities to meet key indicators and facilitate referrals. They will deliver a plan using the Pre-eclampsia application tool on their smart phone and then they can refer the pregnant woman for enrollment for facility care and track them as per key indicators. The key innovation is that the mHealth platform can detect increases in BP within each patient, and this ability to detect is brought down to the community level through CHWs. This will allow for earlier detection of PE as singular BPs. Nurses will receive protocolized instructions and education regarding when to refer a woman to a higher-level facility for further management. The program consists of SMS component delivered to provide information about participant's condition to relevant members of the referral pathway to enhance referrals and facilitate community level follow up.
Study NCT03446742 — intervention group
Intervention type: OTHER
Intervention: Cardiovascular rehabilitation
Description: The cardiovascular rehabilitation program is performed three times weekly on alternate days and each session lasts approximately 60 minutes divided as follows: 5 minutes to the initial rest where blood pressure (BP), heart rate (HR) and signs and symptoms are assessed; 15 minutes of warm-up, composed by global stretches, lower and upper limb exercises, and exercises combining the two modes; then, patients go to the resistance phase (30 minutes), where are performed an individualized aerobic protocol according to their HR reserve values using bicycle and treadmill (at the 4th and 10th minute of both ergometers at HR is evaluated, and in the bicycle is also evaluated the BP of all the patients). The end of the protocol is composed of 10-minute relaxation, during which the patients perform a small cardiovascular deceleration (a few laps around the room, with free speed) and, finally, lie down at rest. The presence of signs and symptoms is assessed at all stages of the program.
Study NCT03826979 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pliates method treatment
Description: The participants undergo to a physical therapy rehabilitation program through the Pilates Method for 2 months.
Study NCT01034488 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Suine
Description: 5000UI/mL
Study NCT04402476 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Powder Free Polychloroprene Surgical Gloves, Sterile. Low Dermatitis Potential, tested for use with Chemotherapy drugs.
Description: Approximately 2cm x 2cm square positioned to ensure that the inside portion of the test material maintained skin contact.
Study NCT02838563 — intervention group
Intervention type: OTHER
Intervention: SIWA
Description: To investigate the scale reliability over time, SIWA are assessed twice, ten minutes apart. To investigate the validity of the tool, SIWA is correlated with another quality of life questionnaire (QoL-AD), a quality of health scale including an analog portion (EQ 5D), and a behavioral disorder scale (Neuropsychiatric Inventory, NPI).
Study NCT01110707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human follicle stimulating hormone (r-hFSH)
Description: Subjects will receive subcutaneous injection of recombinant human follicular stimulating hormone (r-hFSH) 300-450 International Units (IU) administered after pituitary desensitization according to the ovarian response with gonadotrophin-releasing hormone agonist (GnRH-a; at a dose of 0.1 milligram per day \[mg/day\]).
Study NCT01110707 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant human luteinizing hormone (r-hLH)
Description: Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
Study NCT01110707 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Recombinant human luteinizing hormone (r-hLH)
Description: Subjects will receive subcutaneous injection of recombinant human luteinizing hormone (r-hLH) 150 IU/day until the end of ovarian stimulation.
Study NCT01998633 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Hematopoietic Stem Cell Transplant
Description: NOTE: The - sign is the number of days before the transplant and the + sign is the number of days after the transplant.~* Alemtuzumab 0.2mg/kg Day-14,-13,-12,-11,-10~* Fludarabine 30 mg/m2 on Day -8,-7,-6,-5,-4~* Melphalan 140mg/m2 on Day -3~The GVHD prophylaxis will consist of the following:~* Cyclosporine on Day -3 to Day +100, maintaining a level of 250-500 ng/mL, then taper to Day +180.~* Methylprednisolone 2 mg/kg/day on Day -2 and -1, 1 mg/kg/day on Day 0 to Day +28, then taper over 1 month. Oral prednisone may be substituted starting on Day 0 (1.2 mg/kg/day)
Study NCT03711045 — intervention group
Intervention type: BEHAVIORAL
Intervention: eye-tracking
Description: After completing a demographics form, theBeck Depression Inventory,Beck Anxiety Inventory,Barratt Impulsiveness Scale and Ruminative Response Scale-21, each participant has to go to the eye-tracking room and seats in a height adjustable chair and places their chin in a chin rest which was positioned to make sure all participants' eye are in the same location relative to the camera and the monitor.~There are 18 trials and 2 filler trials in the free-view task, each of which contains 4 pictures on the same screen for 25 seconds. There is also a gap screen between each trial lasting for 2 seconds when participants were asked to fixate in the center of the screen. During the experiment, participants are instructed to watch the screen as naturally as possible, and the initial location of the fixation of each trial and the total dwell time of each emotional images(negative, happy, neutral and suicide-related)and the changes of the pupil size were recorded.
Study NCT03914040 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IPSE program
Description: 1. Pre-immersion preparation. A self-study course will be offered about lifestyle modification. Some readings will be suggested to introduce students to the concepts of health promotion and prevention of metabolic syndrome.~2. Immersion. Four different learning methods will be provided: I) four hours of didactic lectures followed by group discussion, II) four hours per student of role playing, III) 30' per students of standardized patient experiences and IV) 30' per students of a new immersive advanced simulation learning environment (e-REAL). Four case-studies will be used to create scenarious, including woman with menopause weight gain, obese young adult, obese child and adult with unhealthy behaviours.
Study NCT01362374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-FU
Description: 5-FU at a dose level of 400 mg/m\^2 as intravenous (IV) injection followed by a dose of 2400 mg/m\^2 as IV infusion over 46 hrs will be administered on Day 1 of each 14-day cycle until disease progression or unacceptable toxicity.
Study NCT01362374 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered at dose level of 75 mg/m\^2 as IV infusion over 1 hr on Day 1 of each 21-day cycle until disease progression or unacceptable toxicity.